Lifecycle Continuity Through Regulatory Compliance: A Comparative Evaluation of Post-Approval Change Strategies for APIs and Drug Products Under the Regulatory Frameworks of Saudi Arabia, the United States, Australia, and Eurasia

The paper presents a parallel assessment of after-clearance change demands for drug substances between the regulatory structures of Saudi Arabia, US, Australia, and the Eurasian Economic Union. The regulatory structures that steer these changes in each area are fundamental for the upkeep of drug safety, usefulness, and standards as healthcare advances. The research strategy calls for a careful study of relevant standards, rules, and case assessments from all named realms. Key aspects such as the nature of amendments, data demands, clearance pathways, and treatment schedules are analyzed to understand the challenges of regulatory adherence. Added to that, the effect of these demands on market ventures, advancement, and access to treatments has been evaluated.

In conclusion, The Review also explain that this comparative analysis demonstrates that while Saudi Arabia, US, FDA, Australia, and Eurasian Economic Union regulations on API and drug product post-approval change management are all risk-based and critical to continued safety, efficacy, and quality, these regulations also vary with respect to classification, data, and timelines.